Abstract Details

Title Artificial Intelligence in the Prehospital Stage of Stroke: Can Virtual Assistants Optimize Triage?

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 4-019

Objective This study describes the development, refinement, and clinical validation of a virtual assistant (VA) based on AI for early stroke detection and appropriate emergency referral.

Background Many patients fail to access emergency services in time for acute stroke treatment. Artificial intelligence (AI) may help optimize prehospital triage.

Design/Methods A prospective cohort study was conducted between August 2024 and July 2025 in a tertiary care center in Buenos Aires, Argentina. The VA was applied to adult inpatients with acute stroke in a neurovascular unit. Prior to this, the tool had been optimized using a literature review and simulations with 1151 de-identified medical records. Clinical, demographic, and performance variables were recorded. The main outcomes were syndromic diagnostic accuracy, identification of the most probable diagnosis, appropriate emergency referral, and user satisfaction.

Results A total of 78 participants were included (median age: 73 years; 56.4% male). In 76.9% of cases, the VA was used by the patient, and in 23.1% by a companion. The mean time from symptom onset to VA use was 2 days. Final diagnoses were ischemic stroke (80.8%), transient ischemic attack (11.5%), subarachnoid hemorrhage (5.1%) and intracerebral hemorrhage (2.6%). Syndromic diagnosis matched the clinical standard in 89.7% of cases; top-1 match in 71.8% and top-3 in 91%. Emergency referral was adequate in 93.6%. Median use involved 10 questions and 4 minutes. Over 90% rated the experience 4 or 5 out of 5.

Conclusions The AI-based VA demonstrated strong diagnostic and referral performance, with high user satisfaction. The next step is its initial supervised implementation in clinical practice.

Authors/Disclosures
Agostina L. Kañevsky, Jr., MD (FLENI) PRESENTER	Miss Kañevsky has nothing to disclose.
Lucas Alessandro, Sr., MD (FLENI)	Dr. Alessandro has nothing to disclose.
Santiago Crema, Jr., MD (FLENI)	Dr. Crema has received research support from Fundación Dr. Manuel Sadosky - CABA, Argentina .
Nicolas bianciotti, MS	Mr. bianciotti has nothing to disclose.
josefina lomban, MS	Miss lomban has nothing to disclose.
Carolina Perez Arana	Carolina Perez Arana has nothing to disclose.
Franco G. BORDON ORSINGHER, MD	Mr. BORDON ORSINGHER has nothing to disclose.
Virginia A. Pujol Lereis, MD (FLENI)	Dr. Pujol Lereis has nothing to disclose.
Sebastian F. Ameriso, MD	Dr. Ameriso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PHRI. Dr. Ameriso has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bayer, Boehringer, Abbott, AstraZeneca.
Diego Fernandez Slezak, PhD	Dr. Fernandez Slezak has nothing to disclose.
Mauricio F. Farez, MD (FLENI)	Dr. Farez has received personal compensation for serving as an employee of Entelai. Dr. Farez has stock in Entelai. The institution of Dr. Farez has received research support from Fundación Sadosky.

��ɫ��

��ɫ��